TOBI Faculty, C. David B. M. Harrell, PhD, OF, FRIPH, with Robert E. Marx, DDS demonstrated the CD34+ cell functions as a central signaling cell to mesenchymal stem cells and osteoprogenitor cells in bone regeneration.
The procedure involved 40 participants, in two randomized groups. Eight of 20 group A patients (an in situ tissue-engineered graft containing 54 ± 38 CD34+ cells/mL along with 54 ± 38 CD44+, CD90+, and CD105+ cells/mL together with rhBMP-2 in an absorbable collagen sponge (1 mg/cm of defect) and crushed cancellous allogeneic bone) with 40% achieving the primary endpoint of mature bone regeneration, whereas all 20 group B patients (same graft, except the CD34+ cell concentration was 1,012 ± 752 cells/mL) with 100% achieving the primary endpoint. CD34+ cell counts above 200/mL are directly correlated to clinically successful bone regeneration
Given the study results, further investigation is warranted to demonstrate the CD34+ cell benefits in bone regeneration in other areas of the body.
Marx, RE and Harrell, DB. (2012). Translational research: The CD34+ cell is crucial for large-volume bone regeneration from the milieu of bone marrow progenitor cells in craniomandibular reconstruction.
Oral Craniofac Tissue Eng; 2:253-271.
Dr. Harrell will present this study at The Othobiologic Institute (TOBI) 4th Annual PRP & Regenerative Medicine Symposium, June 7-8, 2013 in Los Angeles.
Join these field leaders advancing biologics to discuss the latest research, clinical experiences and best-practices at The Orthobiologic Institute (TOBI) 4th Annual PRP & Regenerative Medicine Symposium, June 7-8, 2013 in Los Angeles.
Attend TOBI live or online, details at www.prpseminar.com
Now more than ever is the time to work together and create protocols and standardization of our exploding field.
CME Cadaver Lab: Hands-on Ultrasound-guided Injections & Bone Marrow Aspirate will sell out – Secure your spot at www.prpseminar.com